Evaluation of Symbicort® Turbuhaler® (Budesonide/Formoterol) in Chronic Obstructive Pulmonary Disease (COPD)

Last updated: January 21, 2011
Sponsor: AstraZeneca
Overall Status: Completed

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT00837629
NIS-RSI-SYM-2006/1
  • Ages > 18
  • All Genders

Study Summary

This non-interventional study is to analyse the therapeutic effectiveness in patients with severe COPD following a generally accepted 12-week treatment period with Symbicort Turbuhaler, which could anyhow be shortened or extended at physician's discretion.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • non pregnant female

  • COPD with persistent symptoms in spite of regular bronchodilator therapy

  • Naive or fixed combination treated patients including patients already on SymbicortTurbuhaler

Exclusion

Exclusion Criteria:

  • Hypersensitivity to budesonide, formoterol or inhaled lactose

Study Design

Total Participants: 743
Study Start date:
February 01, 2007
Estimated Completion Date:
September 30, 2007